Welcome to Peptide Card of AntiTbPdb
This page displays user query in tabular form. |
K-(boroMet) details |
Primary information | |
---|---|
ID | antitb_1279, |
Name | 25759383 |
N-Terminal modification | Inhibitor 8 |
C-Terminal Modification | K-(boroMet) |
Chemical Modification | Addition of N-picolinoyl |
Linear/Cyclic | Free |
Length | boroMet = methionine boronic acid |
Chirality | Linear |
Nature | 2 |
Source | L |
Species | Synthetic |
Strain | substrate-based boronate inhibitors |
Inhibition Concentration | Mycobacterium tuberculosis |
In Vitro/ In vivo | Mycobacterium tuberculosis H37Rv |
Cell Line | MIC50 = 6 μM |
Inhibition Concentration | In vitro |
Sequence | 2015 |
Cytotoxicity | Myeloma cells (MM1.S) |
In vivo Model | NA |
Lethal Dose | No cytotoxicty |
Immune Responce | None |
Mechanism of Action | NA |
Target | NA |
Combination Therapy | Inhibit ClpP1P2 peptidase activity and protein degradation in the presence of ClpC1 and ClpX ATPases. |
Other activities | ClpP1P2 peptidase |
PMID | None |
Year of Publication | None |
Tertiary Structure (Technique) | Not Predicted), |
Primary information | |
---|---|
ID | antitb_1280, |
Name | 25759383 |
N-Terminal modification | Inhibitor 9 |
C-Terminal Modification | K-(boroMet) |
Chemical Modification | Addition of N-(3-Phenyl)propanoyl) |
Linear/Cyclic | Free |
Length | boroMet = methionine boronic acid |
Chirality | Linear |
Nature | 2 |
Source | L |
Species | Synthetic |
Strain | substrate-based boronate inhibitors |
Inhibition Concentration | Mycobacterium tuberculosis |
In Vitro/ In vivo | Mycobacterium tuberculosis H37Rv |
Cell Line | MIC50 = 3 μM |
Inhibition Concentration | In vitro |
Sequence | 2015 |
Cytotoxicity | Myeloma cells (MM1.S) |
In vivo Model | NA |
Lethal Dose | No cytotoxicty |
Immune Responce | None |
Mechanism of Action | NA |
Target | NA |
Combination Therapy | Inhibit ClpP1P2 peptidase activity and protein degradation in the presence of ClpC1 and ClpX ATPases. |
Other activities | ClpP1P2 peptidase |
PMID | None |
Year of Publication | None |
Tertiary Structure (Technique) | Not Predicted), |
Primary information | |
---|---|
ID | antitb_1281, |
Name | 25759383 |
N-Terminal modification | Inhibitor 10 |
C-Terminal Modification | K-(boroMet) |
Chemical Modification | Addition of N-(Benzyl) |
Linear/Cyclic | Free |
Length | boroMet = methionine boronic acid |
Chirality | Linear |
Nature | 2 |
Source | L |
Species | Synthetic |
Strain | substrate-based boronate inhibitors |
Inhibition Concentration | Mycobacterium tuberculosis |
In Vitro/ In vivo | Mycobacterium tuberculosis H37Rv |
Cell Line | MIC50 = 6 μM |
Inhibition Concentration | In vitro |
Sequence | 2015 |
Cytotoxicity | Myeloma cells (MM1.S) |
In vivo Model | NA |
Lethal Dose | No cytotoxicty |
Immune Responce | None |
Mechanism of Action | NA |
Target | NA |
Combination Therapy | Inhibit ClpP1P2 peptidase activity and protein degradation in the presence of ClpC1 and ClpX ATPases. |
Other activities | ClpP1P2 peptidase |
PMID | None |
Year of Publication | None |
Tertiary Structure (Technique) | Not Predicted), |
Primary information | |
---|---|
ID | antitb_1282, |
Name | 25759383 |
N-Terminal modification | Inhibitor 11 |
C-Terminal Modification | K-(boroMet) |
Chemical Modification | Addition of N-(2-(3,5-Difluorophenyl)acetyl) |
Linear/Cyclic | Free |
Length | boroMet = methionine boronic acid |
Chirality | Linear |
Nature | 2 |
Source | L |
Species | Synthetic |
Strain | substrate-based boronate inhibitors |
Inhibition Concentration | Mycobacterium tuberculosis |
In Vitro/ In vivo | Mycobacterium tuberculosis H37Rv |
Cell Line | MIC50 = 6 μM |
Inhibition Concentration | In vitro |
Sequence | 2015 |
Cytotoxicity | Myeloma cells (MM1.S) |
In vivo Model | NA |
Lethal Dose | No cytotoxicty |
Immune Responce | None |
Mechanism of Action | NA |
Target | NA |
Combination Therapy | Inhibit ClpP1P2 peptidase activity and protein degradation in the presence of ClpC1 and ClpX ATPases. |
Other activities | ClpP1P2 peptidase |
PMID | None |
Year of Publication | None |
Tertiary Structure (Technique) | Not Predicted), |
Primary information | |
---|---|
ID | antitb_1285, |
Name | 25759383 |
N-Terminal modification | Inhibitor 13 |
C-Terminal Modification | K-(boroMet) |
Chemical Modification | Addition of N-(1H-benzo(b)thiophene-7-carbonyl |
Linear/Cyclic | Free |
Length | boroMet = methionine boronic acid |
Chirality | Linear |
Nature | 2 |
Source | L |
Species | Synthetic |
Strain | substrate-based boronate inhibitors |
Inhibition Concentration | Mycobacterium tuberculosis |
In Vitro/ In vivo | Mycobacterium tuberculosis H37Rv |
Cell Line | MIC50 = 12 μM |
Inhibition Concentration | In vitro |
Sequence | 2015 |
Cytotoxicity | Myeloma cells (MM1.S) |
In vivo Model | NA |
Lethal Dose | No cytotoxicty |
Immune Responce | None |
Mechanism of Action | NA |
Target | NA |
Combination Therapy | Inhibit ClpP1P2 peptidase activity and protein degradation in the presence of ClpC1 and ClpX ATPases. |
Other activities | ClpP1P2 peptidase |
PMID | None |
Year of Publication | None |
Tertiary Structure (Technique) | Not Predicted), |
Primary information | |
---|---|
ID | antitb_1286, |
Name | 25759383 |
N-Terminal modification | Inhibitor 14 |
C-Terminal Modification | K-(boroMet) |
Chemical Modification | Addition of N-(Phenylmetanesulfonyl) |
Linear/Cyclic | Free |
Length | boroMet = methionine boronic acid |
Chirality | Linear |
Nature | 2 |
Source | L |
Species | Synthetic |
Strain | substrate-based boronate inhibitors |
Inhibition Concentration | Mycobacterium tuberculosis |
In Vitro/ In vivo | Mycobacterium tuberculosis H37Rv |
Cell Line | MIC50 = 200 μM |
Inhibition Concentration | In vitro |
Sequence | 2015 |
Cytotoxicity | Myeloma cells (MM1.S) |
In vivo Model | NA |
Lethal Dose | No cytotoxicty |
Immune Responce | None |
Mechanism of Action | NA |
Target | NA |
Combination Therapy | Inhibit ClpP1P2 peptidase activity and protein degradation in the presence of ClpC1 and ClpX ATPases. |
Other activities | ClpP1P2 peptidase |
PMID | None |
Year of Publication | None |
Tertiary Structure (Technique) | Not Predicted), |